2'-RIBOTAC-U for COVID-19

2'-RIBOTAC-U has been reported as potentially beneficial for COVID-19 in the following study.

COVID-19 involves the interplay of 350+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 10,000+ potential treatments. c19early.org analyzes 200+ treatments. We have not reviewed 2'-RIBOTAC-U in detail.

Study suggesting benefit with 2'-RIBOTAC-U

Min et al., Developing nucleoside tailoring strategies against SARS-CoV-2 via ribonuclease targeting chimera, Science Advances, doi:10.1126/sciadv.adl4393

In response to the urgent need for potent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapeutics, this study introduces an innovative nucleoside tailoring strategy leveraging ribonuclease targeting chimeras. By seamlessly integrating ribonuclease L recruiters into nucleosides, we address RNA recognition challenges and effectively inhibit severe acute respiratory syndrome coronavirus 2 replication in human cells. Notably, nucleosides tailored at the ribose 2′-position outperform those modified at the nucleobase. Our in vivo validation using hamster models further bolsters the promise of this nucleoside tailoring approach, positioning it as a valuable asset in the development of innovative antiviral drugs.